MRI + Psilocybin + Risperidone for anhedonia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Nov 2025: Trial started, NCT07490353
  2. 24 Mar 2026: Trial registered, NCT07490353

The trials

NCT07490353: Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

State
Under way
Phase
Phase 1
People
85 planned
Started
1 Nov 2025
Primary completion
31 May 2028
Arms
Psilocybin first, psilocybin + risperidone second, Psilocybin + risperidone first, psilocybin second
Results
None posted
  1. 1 Nov 2025: Trial started
  2. 24 Mar 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.